Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine

Lee, Byeong-Jae; Kwon, Hyeok‐il; Kim, Eunha; Park, Su‐Jin; Lee, Sang-Ho; Choi, Young Ki; Kim, Sang-Hyun

doi:10.7774/cevr.2014.3.2.194

Cited by 8 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the MF59 adjuvant was compared with the PA adjuvant in this study. In agreement with previous reports [35, 40–42], the results showed that the antigen-specific serum IgG GMTs and post-vaccination HI GMTs for both the A/H1N1 and A/H3N2 strains were significantly improved by the MF59 adjuvant and were significantly higher than the GMTs obtained with the vaccine alone. These effects were observed in the two PA-adjuvanted vaccine groups, although the serum IgA and mucosal SIgA GMTs were significantly enhanced by the high-dose PA adjuvant compared to the MF59 adjuvant.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

et al. 2017

View full text Add to dashboard Cite

Intranasal vaccination is more potent than parenteral injection for the prevention of influenza. However, because the poor efficiency of antigen uptake across the nasal mucosa is a key issue, immunostimulatory adjuvants are essential for intranasal vaccines. The immunomodulator mannatide or polyactin (PA) has been used for the clinical treatment of impaired immunity in China, but its adjuvant effect on an inactivated trivalent influenza vaccine (ITIV) via intranasal vaccination is unclear. To explore the adjuvant effect of PA, an inactivated trivalent influenza virus with or without PA or MF59 was instilled intranasally once a week in BALB/c mice. Humoral immunity was assessed by both the ELISA and hemagglutination inhibition (HI) methods using antigen-specific antibodies. Splenic lymphocyte proliferation and the IFN-γ level were measured to evaluate cell-mediated immunity. The post-vaccination serum HI antibody geometric mean titers (GMTs) for the H1N1 and H3N2 strains, antigen-specific serum IgG and IgA GMTs, mucosal SIgA GMT, splenic lymphocyte proliferation, and IFN-γ were significantly increased in the high-dose PA-adjuvanted vaccine group. The seroconversion rate and the mucosal response for the H3N2 strain were significantly elevated after high-dose PA administration. These adjuvant effects of high-dose PA for the influenza vaccine were comparable with those of the MF59 adjuvant, and abnormal signs or pathological changes were not found in the evaluated organs. In conclusion, PA is a novel mucosal adjuvant for intranasal vaccination with the ITIV that has safe and effective mucosal adjuvanticity in mice and successfully induces both serum and mucosal antibody responses and a cell-mediated response.

show abstract

Section: Discussionsupporting

confidence: 93%

“…The MF59 adjuvant, which is an oil-in-water emulsion, provides immunogenicity and protection against the influenza virus in humans and is the most commonly used adjuvant for influenza virus vaccines [2, 40]. Therefore, the MF59 adjuvant was compared with the PA adjuvant in this study.…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Oil adjuvant, one of the most commonly used adjuvants in domestic animal vaccines, is known to have safety and robust efficacy profiles, with antigen-specific antibodies induced against influenza viruses. It has also been applied to vaccines for low-pathogenicity avian influenza H9N2 vaccines for decades [33,34]. However, H9N2 has not been conquered worldwide, and moreover, outbreaks have been reported in animals vaccinated against H9N2 infection.…”

Section: Discussionmentioning

confidence: 99%

Bacillus subtilis spores as adjuvants against avian influenza H9N2 induce antigen-specific antibody and T cell responses in White Leghorn chickens

Lee

Kye

Park

et al. 2020

Vet Res

View full text Add to dashboard Cite

Low-pathogenicity avian influenza H9N2 remains an endemic disease worldwide despite continuous vaccination, indicating the need for an improved vaccine strategy. Bacillus subtilis (B. subtilis), a gram-positive and endosporeforming bacterium, is a non-pathogenic species that has been used in probiotic formulations for both animals and humans. The objective of the present study was to elucidate the effect of B. subtilis spores as adjuvants in chickens administered inactivated avian influenza virus H9N2. Herein, the adjuvanticity of B. subtilis spores in chickens was demonstrated by enhancement of H9N2 virus-specific IgG responses. B. subtilis spores enhanced the proportion of B cells and the innate cell population in splenocytes from chickens administered both inactivated H9N2 and B. subtilis spores (Spore + H9N2). Furthermore, the H9N2 and spore administration induced significantly increased expression of the pro-inflammatory cytokines IL-1β and IL-6 compared to that in the H9N2 only group. Additionally, total splenocytes from chickens immunized with inactivated H9N2 in the presence or absence of B. subtilis spores were restimulated with inactivated H9N2. The subsequent results showed that the extent of antigen-specific CD4 + and CD8 + T cell proliferation was higher in the Spore + H9N2 group than in the group administered only H9N2. Taken together, these data demonstrate that B. subtilis spores, as adjuvants, enhance not only H9N2 virus-specific IgG but also CD4 + and CD8 + T cell responses, with an increase in pro-inflammatory cytokine production. This approach to vaccination with inactivated H9N2 together with a B. subtilis spore adjuvant in chickens produces a significant effect on antigenspecific antibody and T cell responses against avian influenza virus.

show abstract

“…Previously, it has been shown that co-immunization of OMV increased the antigen-specific immune response to co-delivered antigens in intramuscular vaccination models [11,13]. To investigate whether the intranasal delivery of fmOMV effectively induces strong antigen-specific immune responses, we injected influenza vaccine antigens with various doses of fmOMV (1.0-10 lg)…”

Section: Co-administration Of Fmomv Increases Systemic Antibody and Tmentioning

confidence: 99%

“…Due to the nature of these components, OMVs can stimulate the host immune system through innate immune receptors, including toll-like receptors (TLRs) and NOD-like receptors (NLRs) [9]. In recent studies, intramuscular injection of OMV with irrelevant antigens enhanced antigen-specific humoral and cellular immune responses, and increased the protection rate against tumor and virus challenges [10,11]. However, in order to use OMVs as vaccine adjuvants or delivery vehicles, the safety of this system must be addressed because LPS in OMVs may excessively provoke innate immune responses and lead to endotoxicity.…”

Section: Introductionmentioning

confidence: 99%

Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model

Lee

Kim

Bae

et al. 2017

Vaccine

Self Cite

View full text Add to dashboard Cite

Influenza is an acute respiratory disease and a major health problem worldwide. Since mucosal immunity plays a critical role in protection against influenza virus infection, mucosal immunization is considered a promising vaccination route. However, except for live-attenuated vaccines, there are no effective killed or recombinant mucosal influenza vaccines to date. Outer membrane vesicles (OMVs) are nano-sized vesicles produced by gram-negative bacteria, and contain various bacterial components capable of stimulating the immune system of the host. We generated an OMV with low endotoxicity (fmOMV) by modifying the structure of the lipid A moiety of lipopolysaccharide and investigated its effect as an intranasal vaccine adjuvant in an influenza vaccine model. In this model, fmOMV exhibited reduced toll-like receptor 4-stimulating activity and attenuated endotoxicity compared to that of native OMV. Intranasal injection of the vaccine antigen with fmOMV significantly increased systemic antibody and T cell responses, mucosal IgA levels, and the frequency of lung-resident influenza-specific T cells. In addition, the number of antigen-bearing CD103 dendritic cells in the mediastinal lymph nodes was significantly increased after fmOMV co-administration. Notably, the mice co-immunized with fmOMV showed a significantly higher protection rate against challenge with a lethal dose of homologous or heterologous influenza viruses without adverse effects. These results show the potential of fmOMV as an effective mucosal adjuvant for intranasal vaccines.

show abstract

Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine

Cited by 8 publications

References 26 publications

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

Bacillus subtilis spores as adjuvants against avian influenza H9N2 induce antigen-specific antibody and T cell responses in White Leghorn chickens

Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model

Contact Info

Product

Resources

About